Cancer Research Meeting Calendar EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guttinger, M.
Right arrow Articles by Siccardi, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guttinger, M.
Right arrow Articles by Siccardi, A. G.
[Cancer Research 60, 4211-4215, August 1, 2000]
© 2000 American Association for Cancer Research

Immunology

Adoptive Immunotherapy by Avidin-driven Cytotoxic T Lymphocyte- Tumor Bridging1

Maria Guttinger, Fabrizio Guidi, Marco Chinol, Eva Reali, Fabrizio Veglia, Giovanna Viale, Giovanni Paganelli, Angelo Corti and Antonio G. Siccardi2

Department of Biological and Technological Research [M. G., F. G., E. R., A. C., A. G. S.] and Unit of Biostatistics [F. V.], San Raffaele Scientific Institute, European Institute of Oncology [M. C., G. P.], and Department of Biology and Genetics, University of Milano [E. R., G. V., A. G. S.], I-20132 Milan, Italy


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
We have shown previously that T cells, tagged with biotinylated anti-CD3 antibody fragments, can exert avidin-dependent cytolytic activity on suitably biotinylated tumor cells in vitro. In this study, we demonstrate that avidin-driven CTL-tumor bridging in vivo leads to growth inhibition of murine tumors WEHI-164 fibrosarcoma and RMA lymphoma. The biodistribution of biotin-tagged 111In-labeled T cells demonstrated a selective avidin-dependent and time-dependent accumulation of radioactivity at tumor sites. The specificity of lymphocyte tumor localization was demonstrated by the concurrent time-dependent decrease of radioactivity in the blood and in all other organs. Furthermore, we documented a therapeutic effect of the adoptively transferred T cells, i.e., a significant delay of tumor growth at early stages. All of the experiments included a control group of mice, which received all of the reagents, except avidin. These avidin-minus mice showed no specific localization and no delay in tumor growth, indicating that avidin bridging was essential for T-cell activity at tumor sites.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The normal immune system can react with both humoral and cellular effector arms against malignant cells but rarely represents a significant barrier to tumor growth:

(a) A panoply of mAb3 -defined tumor-associated antigens (B-TAA) is available, but the role of antitumoral antibody response in immune surveillance is controversial (1) .

(b) A substantial number of T-TAAs, recognized by either CD8+ or CD4+ T cells, have been identified (2) . Some of these antigens derive from tumor-specific mutations and some are unmodified shared antigens inappropriately expressed or overexpressed in transformed cells (3) . Although it has been demonstrated, both in vitro and in vivo, that some T-TAAs can function as tumor rejection antigens (4) , a poor correlation between induction of specific T cells and clinical responses has been observed (5) .

(c) The loss of the MHC restricting element or the transporter associated with antigen presentation, which can occur in tumors (6, 7, 8) , can be responsible for the relative inefficiency of T-TAAs as targets for cancer vaccines or immunotherapy. Poor T-TAA presentation can also depend on cytokine action; tumor cell lines expressing IL-10 strongly down-regulate MHC and the transporter associated with antigen presentation (9) .

The advantages of antibody-based targeting and cell-mediated cytolysis have been combined in bispecific antibodies (10) , which mediate tumor cell destruction by bridging a B-TAA on the surface of the tumor cell to a trigger molecule on the effector cell. Major efforts have been focused on TCR/CD3 molecules as trigger elements, sometimes combined with activation enhancers, i.e., costimulatory molecules or cytokines (11, 12, 13) .

Exploiting a similar strategy, we have demonstrated recently that avidin-driven CTL-tumor bridging leads to T cell-mediated, non-MHC restricted cytotoxic activity on tumor cell lines in vitro (14) . Lymphocytes were biotin-tagged by monovalent anti-CD3 antibodies, and tumor cells were pretargeted by biotinylated anti-B-TAA antibodies and avidin. In this report, we show that the same strategy applied in vivo leads to specific accumulation of biotin-tagged lymphocytes at pretargeted tumor sites in a non-MHC-restricted mode and to significant inhibition of tumor growth.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Animals, Cell Lines, and Antibodies.
C57BL/6 and BALB/c mice (females 4 weeks of age) were purchased from Charles River Laboratories (Calco, Italy). All mice were bred under pathogen-free conditions. As experimental tumor models, the Thy 1.1 transfectants of the following cell lines were used: the H-2b T-cell lymphoma RMA-1 (15) , a Rauscher MuLV-induced tumor of C57BL/6 origin, and the H-2d fibrosarcoma WEHI 164 (ATCC # CRL-1751), a methylcolanthrene-induced tumor of BALB/c origin. Thy1.1-expressing cell lines (RMA-T and WEHI-T) were obtained by transfection with a construct encoding the Thy1.1 allele, inserted into the mammalian expression vector pRS1-neo (16) . Cells were maintained in RPMI 1640 supplemented with 50 units/ml penicillin-streptomycin, 2 mM L-glutamine, 50 nM ß-mercaptoethanol, 10% heat-inactivated FCS, and 500 µg/ml G418 (Sigma Chemical Co., St. Louis, MO). mAbs 19E12 (anti-Thy1.1; kindly supplied by Dr. A. Livingstone, Basel Institute for Immunology, Basel, Switzerland) and 2C11 (anti-CD3 epsilon; Ref. 17 ) were obtained either from culture supernatants of hybridoma cells or from ascitic fluids. F(ab')2 fragments of mAb 2C11 were obtained by papain digestion, according to standard protocols. mAb purity was evaluated using SDS-PAGE analysis. F(ab')2 fragment biotinylation was performed as follows. One ml of 0.5 mg/ml antibody solution in sodium bicarbonate buffer (pH 8.8) was mixed with 100 µl of 0.5 mg/ml sulfo-NHS-LC-biotin (Pierce Chemical Co., Rockford, IL) solution. After 4 h incubation at room temperature, 125 µl of 1 M lysine solution were added for 2 additional h. Biotinylated mAbs were dialyzed overnight against PBS.

Flow Cytometry.
Binding and persistence of biotinylated 19E12 on tumor cells and of biotinylated 2C11 F(ab')2 fragments on T cells were evaluated by fluorescence-activated cell sorter analysis. Cells were incubated with 10 µg/ml biotinylated antibodies in PBS, containing 3% FCS, for 1 h on ice. The cells were washed in medium and incubated for 1–24 h and washed and stained with fluorescein-conjugated streptavidin. Mean fluorescence intensity was used to estimate the amount of antibodies bound to the cells at each time point.

Preparation of Biotin-tagged T Cells for Adoptive Transfer.
Activated T cells were obtained from splenocytes isolated from C57BL/6 or BALB/C mice and cultured on anti-CD3-coated 24-well plates in RPMI 1640 supplemented with antibiotics and 10% FCS. After 3 days, recombinant IL-2 (100 units/ml) was added, and T cells were expanded in vitro for 3 additional days. Cells were then collected and incubated with biotinylated 2C11 F(ab')2 fragments (1 µg/106 cells) for 1 h at 4°C. After extensive washing, biotin-tagged cells were suspended in sterile 0.9% NaCl before in vivo adoptive transfer experiments.

In Vivo Studies.
Studies on animal models were approved by the Ethical Committee of the San Raffaele Scientific Institute and performed according to the prescribed guidelines. C57BL/6 and BALB/c mice were inoculated, respectively, with 5 x 104 RMA-T or 7 x 106 WEHI-T cells, in the right flank. At various days after tumor implantation (days 1–4, as indicated for each of the reported experiments), mice were treated with sequential administrations of biotinylated antibodies, avidins, and biotin-tagged T cells, according to the following 3-day protocol: step 1, 40 µg of biotin-mAb 19E12 (i.p.); step 2, after 18 and 19 h, respectively, 60 µg of avidin and 60 µg of streptavidin (i.p.); and step 3, 24 h later, 5–20 x 106 biotin-tagged lymphocytes (i.v.). Steps 1 and 2 are collectively called "pretargeting steps," whereas step 3 is called "adoptive transfer." Each reagent was diluted in sterile 0.9% NaCl. In control experiments, one or more of the above components were replaced with diluent. Where indicated, 2000 units IL-2 were administered i.p. to each mouse for 3 days, starting from the day after adoptive transfer. Each experiment was carried out with five mice/group. Treated mice were monitored every second day for tumor growth by measuring two perpendicular diameters with a caliper. Tumor volume was estimated by calculating V = (ds x ds x dl)/2, where ds and dl are the short and long diameters, respectively. Animals were killed when the tumors became larger than 500–600 cubic mm.

Biodistribution of 111In-labeled Lymphocytes.
Activated biotinylated lymphocytes (~108) were labeled with 29–37 MBq of 111In-Oxine (Mallinckrodt Medical, Petten, Holland), according to reported methods (18) , obtaining a specific activity of 1.0–1.3 MBq/5 x 106 lymphocytes. After the completion of the pretargeting steps on day 5, the adoptive transfer was performed on day 6 by i.v. injection of 5 x 106 biotin-tagged 111In-labeled lymphocytes into BALB/c mice implanted with WEHI-T tumors. After 4 and 24 h from the adoptive transfer, five mice/group were euthanized, and spleen, liver, kidney, lung, bone marrow, blood, urine, and tumor were collected and analyzed for the associated radioactivity in a gamma counter. The results are represented as the mean ± SD of percentage of total dose injected/mg of tissue.

Statistical Analysis.
Tumor sizes are shown as the mean ± SE. Statistical analyses on tumor growth data were performed using covariance analysis. Statistical analyses on survival data were performed using the log rank test.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Adoptive Transfer of Biotin-tagged Lymphocytes.
Avidin bridging of biotinylated lymphocytes and tumor cells in vitro elicits antibody-driven, T cell-mediated, non-MHC-restricted cytotoxic activity (14) . To verify the immunotherapeutic potential of this strategy in vivo, we applied it to two mouse tumor models (BALBc WEHI-T and C57BL/6 RMA-T). Because both mouse strains have a Thy 1.2 genotype, the cell lines were transfected with the Thy 1.1 gene to mimic a unique B-TAA-equivalent, reactive with mAb 19E12 (16) .

Lymphocytes from the spleens of C57BL/6 or BALB/c mice were activated and expanded in vitro by exposure to solid-phase mAb 2C11 (anti-CD3{epsilon}) and to IL-2 (see "Materials and Methods"). After 6 days in culture, T lymphocytes were biotinylated via F(ab')2 proteolytic fragments of the mAb 2C11, which, in the soluble form, do not mediate T-cell activation (not shown).

The persistence on these lymphocytes of biotinylated 2C11 F(ab')2 was measured by flow cytometry. After an initial 30% loss in the first hour, the half-life of the surface anti-CD3 F(ab')2 was about 8 h (Fig. 1Citation ). Conversely, the anti-Thy 1.1 mAb persisted on RMA-T and WEHI-T tumor cells without detectable decrease for at least 24 h (not shown). Biotin-tagged lymphocytes were adoptively transferred into tumor-bearing mice treated with the pretargeting steps (see "Materials and Methods").



View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Dissociation kinetics from activated mouse lymphocytes of biotin-labeled F(ab')2 fragments of the anti-CD3 mAb 2C11. The biotinylated fragments that remained on the cell surface at various times of incubation were measured by fluorescence-activated cell sorter analysis.

 
Tumor Localization.
The effects of tumor pretargeting and lymphocyte tagging on lymphocyte biodistribution were evaluated by tumor localization experiments in the BALB/c WHEI-T model, using biotin-tagged 111In-labeled lymphocytes. The controls were tumor-bearing mice in which one or both pretargeting reagents had been omitted. Animals were sacrificed 4 or 24 h after the adoptive transfer. As shown in Fig. 2Citation , after 4 h, lymphocyte-associated radioactivity could be detected in all compartments, with higher concentrations in lung, kidney, spleen, and liver, and a tumor:blood ratio of 0.5. At 24 h, a selective accumulation of radioactivity in the tumor compartment was observed, and the tumor:blood ratio increased from 0.5 to ~10. The tumor was the only compartment with a time-dependent increase in radioactivity (>2-fold), whereas all other compartments showed a time-dependent decrease. The kinetic pattern shown by the tumor compartment was significantly different (P < 0.01 to P < 0.001) from those of all other compartments. Avidin-minus controls showed significantly lower counts (P < 0.001) only in the tumor compartment. These data indicated that biotin-tagged lymphocytes accumulate and are specifically retained by pretargeted tumors via avidin bridging.



View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Effect of tumor pretargeting and lymphocyte tagging on 111In-labeled lymphocyte biodistribution in the BALB/c WEHI-T experimental tumor model. The pretargeting steps were completed on day 5 from tumor implantation; the adoptive transfer was performed on day 6 (1.1–1.3 MBq/5 x 106 biotin-tagged lymphocytes, i.v.); 4 and 24 h later, five mice/group were euthanized, and the tumor and the indicated fluids and organs were collected and analyzed for the associated radioactivity. The results are represented as the means; bars, SD of percentage of total dose injected/mg of tissue. {diamond}, avidin-minus controls.

 
Statistical analysis demonstrated that the compartments (other than tumor) could be grouped into two groups; blood, urine and lung showed a marked time-dependent decrease in radioactivity, whereas kidney, bone marrow, liver, and spleen showed a less marked decrease. The difference between the two patterns was statistically significant (P < 0.001).

Tumor Therapy.
In the BALB/c WEHI-T model, the adoptive transfer of biotin-tagged lymphocytes at day 5 blocked tumor growth at the volume reached at day 7 in control mice (Fig. 3Citation ). The difference in tumor growth was statistically significant (P < 0.001). The addition to the protocol of three administrations of low-dose rIL-2 (2000 units i.p./mouse at days 6, 7, and 8) further enhanced the antitumor effect, resulting in a block of tumor growth at the size reached at day 6 in control mice, possibly because of a facilitating effect on lymphocyte extravasation. The cytokine treatment had no effect on tumor growth in a control group. The experiments with WEHI tumors can give information only on the early stages of tumor growth, because a spontaneous rejection of the tumor takes place at days 12–13.



View larger version (37K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Delay of tumor growth in the BALB/c WEHI-T tumor model, attributable to the adoptive transfer of biotin-tagged lymphocytes into mice bearing pretargeted tumors ({blacktriangleup}), as compared with the adoptive transfer of the same lymphocytes into non-pretargeted controls ({circ}) and avidin-minus controls ({triangleup}). The pretargeting steps were completed on day 5 from tumor implantation, and the adoptive transfer was performed on day 6. Three administrations of rIL-2 (2000 units i.p./mouse at days 6, 7, and 8) further enhanced the antitumor effect ({blacksquare}), but the cytokine treatment had no effect in avidin-minus control mice ({square}).

 
Conversely, in the C57BL/6 RMA-T model, tumors are very aggressive and result in death by days 15–20. Also in this model, a highly significant delay in tumor growth (P < 0.001) was observed in animals adoptively transferred with biotin-tagged lymphocytes and treated with low-dose rIL-2, whereas incomplete control therapies, lacking one of the steps, did not show any antitumor effect (Fig. 4ACitation and data not shown). The antitumor effect was, in this model, also documented by a marked prolongation of survival (i.e., the time to reach the dimensional end point at which animals have to be sacrificed). In the experiments reported in Fig. 4BCitation , 9 of 10 control animals had to be sacrificed before the first treated animal reached the end point, the difference between the survival curves being highly significant (P < 0.001).



View larger version (23K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. A, delay of tumor growth in the C57BL/6 RMA-T tumor model, attributable to the adoptive transfer of 5 x 106 ({blacktriangleup}) or 2 x 107 ({blacksquare}) biotin-tagged lymphocytes into mice bearing pretargeted tumors, as compared with the adoptive transfer of the same numbers of lymphocytes into avidin-minus control mice (open symbols). The pretargeting steps were completed on day 5 from tumor implantation, and the adoptive transfer was performed on day 6. All mice also received three administrations of rIL-2 (2000 units i.p./mouse at days 6, 7, and 8). B, difference in survival (i.e., the time to reach the dimensional end point at which animals have to be sacrificed) between the pooled treated animals (•) and the pooled avidin-minus controls ({circ}).

 
In one experiment, where the adoptive transfer of biotin-tagged lymphocytes was performed earlier (completed at day 3), no antitumor effect could be observed (not shown), consistent with the notion that tumor vascularization starts around day 5 and that, at that date, the concentration of biotinylated 2C11 F(ab')2 fragments on the surface of lymphocytes might have become too low to mediate homing to the tumor.


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The safety and the clinical proficiency of a pretargeting "three-step method" based on avidin-biotin bridging to deliver radioisotopes selectively to tumors have been demonstrated conclusively (19, 20, 21) . The method consists of the following steps: biotinylated anti-B-TAA monoclonal antibodies (first step) and, 1 day later, avidin (second step) are administered to the patient; a biotin-tagged chelate-radioisotope complex (third step) is then administered after a suitable interval, when avidin and avidin-biotinylated antibody complexes have been removed from the circulation (22, 23, 24) . The biotin-tagged radioisotope is then selectively retained by the avidin bound on the tumor cell surface or rapidly lost through the kidney, reaching tumor:background ratios of 20–100. Both diagnostic and therapeutic applications have been described and introduced into clinical practice (21, 22, 23) .

Because of its tetravalency, tumor-bound avidin is potentially able to function as an "artificial receptor" for a variety of effectors, provided that they are biotinylated. The selectivity is guaranteed by the very efficient liver-mediated clearance of circulating avidin and avidin-biotin complexes, which ensures that, just 4 hours after avidin administration, the only accessible avidin in the organism is that which is bound to the tumor. The artificial avidin receptor has been successfully used to selectively direct biotinylated TNF-{alpha} onto tumors (24) .

The aim of the present work was to exploit the artificial avidin receptor for redirecting biotinylated autologous cytotoxic cells onto tumors (in a non-TCR-specific, non-MHC-restricted mode) to obtain selective, avidin-driven, in situ activation of cytotoxic potentials. The selective biotinylation of a trigger molecule such as CD3 (achieved by treating the cells with biotinylated anti-CD3 antibody fragments) drives the selective killing of avidinated tumor targets in vitro; conversely, chemically biotinylated lymphocytes, although fully viable, fail to kill avidinated tumor targets (14) .

CD3 aggregation, and therefore activation of the cytotoxic machinery, must occur only on the tumor surface, mediated by avidin bridging. Should such cross-linking occur before, TCR internalization would remove the biotinylated ligand from the cell surface, thus interfering with redirected tumor homing. In our preliminary in vitro work with human lymphocytes and cell lines, we used monovalent scFv reagents, but these have a limited avidity and thus a short half-life (~4 h) on the cell surface, and it is unlikely that they could ever be used in a clinical setting. In mouse experimental systems, anti-CD3 F(ab')2 fragments do not induce T-cell activation, and as shown in Fig. 1Citation , have a longer half-life on the cell surface (~8 h), more likely to be enough for localization purposes.

Biotin-tagged radioactive lymphocytes showed a background biodistribution in avidin-minus control mice qualitatively and quantitatively analogous to that reported for adoptively transferred 111In- labeled tumor-infiltrating lymphocytes in metastatic melanoma patients (25) . The effect of avidin was dramatic; the tumor:blood ratio, which was 0.5 at 4 h, was inverted and grew to about 10 at 24 h, the tumor being the only compartment with a time-dependent increase in radioactivity, while all other compartments showed a time-dependent decrease.

In essence, the results demonstrate that: (a) avidin can efficiently drive homing of biotin-tagged lymphocytes to pretargeted tumor sites; and (b) redirected lymphocytes display antitumor activity in two mouse tumor models in vivo. We have therefore reached the same goals sought by bifunctional antibody strategies. However, the availability of reagents, the ease of biotinylation, the complete and reliable avidin-driven clearance of biotinylated antibodies, the high affinity of avidin-biotin interaction, and the possibility of using antibody combinations (to avoid the escape of antigen-negative tumor variants) are clear advantages of this approach, as compared with bispecific antibodies. Moreover, separating lymphocyte tagging from tumor pretargeting allows optimization of each step independently from the other, thus allowing construction, on a given tumor, of an "optimal" artificial receptor, which could even be reliably monitored with a biotinylated radioisotope in tracer amounts.

An appealing evolution of this strategy could be to use genetically modified T cells expressing a chimeric TCR composed of an avidin-reactive extracellular moiety and of the signal transducing sequence of the {zeta} chain of the TCR/CD3 complex. CTLs expressing antigen-reactive chimeric receptors (T-bodies) have been shown to have cytotoxic activity against tumors both in vitro and in vivo (26, 27, 28, 29) . The major drawback of T-bodies was the inhibition of chimeric receptor activity by soluble antigen, thus limiting their application only to integral membrane protein target antigens (29) . This limitation should not exist for avidin-reactive CTLs, because avidin would be completely cleared from the circulation at the time of adoptive transfer.


   ACKNOWLEDGMENTS
 
We thank Jack Greiner, Doug Grosenbach, and Helen Sabzevari for critical reading of the manuscript.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by grants from the Associazione Italiana Ricerca sul Cancro, Progetto Finalizzato Biotecnologie of the Consiglio Nazionale delle Ricerche, Ministero dell’Università e della Ricerca Scientifica, and Programma AIDS, Istituto Superiore di Sanità. Back

2 To whom requests for reprints should be addressed, at Department of Biological and Technological Research, San Raffaele Scientific Institute, via Olgettina 58, I-20132 Milan, Italy. E-mail: siccardi.antonio{at}hsr.it Back

3 The abbreviations used are: mAb, monoclonal antibody; B-TAA and T-TAA, B cell- and T cell-defined tumor associated antigen, respectively; IL, interleukin; TCR, T-cell receptor; rIL, recombinant IL. Back

Received 12/ 7/99. Accepted 5/30/00.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Alexandroff A. B., Robins R. A., Murray A., James K. Tumour immunology: false hopes–new horizons?. Immunol. Today, 19: 247-250, 1998.[Medline]
  2. Van den Eynde B., van der Bruggen P. T cell defined tumor antigens. Curr. Opin. Immunol., 9: 684-693, 1997.[Medline]
  3. Wolfel T., Hauer M., Schneider J., Serrano M., Wolfel C., Klehmann-Hieb E.,, De Plaen E.,, Hankeln T., Meyer zum Buschenfelde K-H.,, Beach D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (Washington DC), 269: 1281-1284, 1995.[Abstract/Free Full Text]
  4. Boon T., Old L. Cancer tumor antigens. Curr. Opin. Immunol., 9: 681-683, 1997.[Medline]
  5. Bellone M., Iezzi G., Imro M. A., Protti M. P. Cancer immunotherapy: synthetic and natural peptides in the balance. Immunol. Today, 20: 457-462, 1999.[Medline]
  6. Uyttenhove C., Maryanski J., Boon T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med., 157: 1040-1052, 1983.[Abstract/Free Full Text]
  7. Garrido F., Ruiz-Cabello F., Cabrera T., Perez-Villar J., Lopez-Botet M., Duggan-Keen M., Stern P. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol. Today, 18: 89-95, 1997.[Medline]
  8. Seliger B., Maeurer M., Ferrone S. TAP off– tumors on. Immunol. Today, 18: 292-299, 1997.[Medline]
  9. Petersson M., Charo J., Salazar-Onfray F., Noffz G., Mohaupt M., Qin Z., Klein G., Blankenstein T., Kiessling R. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J. Immunol., 161: 2099-2105, 1998.[Abstract/Free Full Text]
  10. von Mehren M., Weiner L. M. Monoclonal antibody-based therapy. Curr. Opin. Oncol., 8: 493-498, 1996.[Medline]
  11. Holliger P., Manzke O., Span M., Hawkins R., Fleischmann B., Qinghua L., Wolf J., Diehl V., Cochet O., Winter G., Bohlen H. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Cancer Res., 59: 2909-2916, 1999.[Abstract/Free Full Text]
  12. Li Q., Furman S. A., Bradford C. R., Chang A. E. Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation. Clin. Cancer Res., 5: 461-469, 1999.[Abstract/Free Full Text]
  13. Elsasser D., Stadick H., Stark S., Van de Winkel J. G., Gramatzki M., Schrott K. M., Valerius T., Schafhauser W. Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma. Anticancer Res., 19: 1525-1528, 1999.[Medline]
  14. Guidi F., Spagnoli G., Neri G., Paganelli G., Siccardi A. G., Guttinger M. Three-step tumor targeting via biotin-avidin interaction as a versatile system to elicit T cell mediated, non MHC restricted cytotoxic activity against neoplastic cells. Int. J. Cancer, 76: 443-447, 1998.[Medline]
  15. Ljunggren H-G., Kärre K. Host resistance directed selectively against H2-deficient lymphoma variants. J. Exp. Med., 162: 1745-1749, 1985.[Abstract/Free Full Text]
  16. Moro M., Pelagi M., Fulci G., Paganelli G., Dellabina P., Casorati G., Siccardi A. G., Corti A. Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor {alpha}. Cancer Res., 57: 1922-1928, 1997.[Abstract/Free Full Text]
  17. Leo O., Foo M., Sachs D. H., Samelson L. E., Bluestone J. A. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl. Acad. Sci. USA, 84: 1374-1378, 1987.[Abstract/Free Full Text]
  18. Thakur M., Lavender J., Arnot R., Silvester D., Segal A. Indium-111-labeled lymphocytes in man. J. Nucl. Med., 18: 1012-1019, 1977.
  19. Paganelli G., Magnani P., Zito F., Villa E., Sudati F., Lopalco L., Rossetti C., Malcovati M., Chiolerio F., Seccamani E., Siccardi A. G., Fazio F. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen positive patients. Cancer Res., 51: 5960-5966, 1991.[Abstract/Free Full Text]
  20. Siccardi A. G., Paganelli G., Pontiroli A., Pelagi M., Magnani P., Viale G., Faglia G., Fazio F. In vivo imaging of chromogranin A positive endocrine tumors by three-step monoclonal antibody targeting. Eur. J. Nucl. Med., 23: 1455-1459, 1996.[Medline]
  21. Paganelli G., Grana C., Chinol M., Cremonesi M., De Cicco C., Debraud F., Robertson C., Zurridda S., Casadio C., Zoboli S., Siccardi A. G., Veronesi U. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur. J. Nucl. Med., 26: 348-357, 1999.[Medline]
  22. Paganelli G., Magnani P., Siccardi A. G., Fazio F. Clinical application of the avidin-biotin system for tumor targeting Goldenberg D. eds. . Cancer Therapy with Radiolabeled Antibodies, : 239-254, CRC Press New York 1995.
  23. Paganelli G., Samuel A., Magnani P., Siccardi A. G., Fazio F. Potential of the avidin-biotin system for diagnostic application Torchilin V. eds. . Handbook of Targeted Delivery of Imaging Agents, : 289-302, CRC Press New York 1995.
  24. Gasparri A., Moro M., Curnis F., Sacchi A., Pagano S., Veglia F., Casorati G., Siccardi A. G., Dellabona P., Corti A. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor {alpha} in mouse models. Cancer Res., 59: 2917-2923, 1999.[Abstract/Free Full Text]
  25. Fisher B., Packard B. S., Read E. J., Carrasquillo J. A., Carter C. S., Topalian S. L., Yang J. C., Yolles P., Larson S. M., Rosenberg S. A. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J. Clin. Oncol., 7: 250-261, 1989.[Abstract]
  26. Hwu P., Shafer G. E., Treisman J., Schindler D. G., Gross G., Cowherd R., Rosenberg S. A., Eshhar Z. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J. Exp. Med., 178: 361-366, 1993.[Abstract/Free Full Text]
  27. Hwu P., Yang J. C., Cowherd R., Treisman J., Shafer G. E., Eshhar Z., Rosenberg S. A. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res., 55: 3369-3373, 1995.[Abstract/Free Full Text]
  28. Weijtens M. E., Willemsen R. A., Valerio D., Stam K., Bolhuis R. L. Single chain Ig/{gamma} gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J. Immunol., 157: 836-843, 1996.[Abstract]
  29. Eshhar Z. Tumor-specific T-bodies: towards clinical application. Cancer Immunol. Immunother., 45: 131-136, 1997.[Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
V. S. Zimmermann, A. Bondanza, A. Monno, P. Rovere-Querini, A. Corti, and A. A. Manfredi
TNF-{alpha} Coupled to Membrane of Apoptotic Cells Favors the Cross-Priming to Melanoma Antigens
J. Immunol., February 15, 2004; 172(4): 2643 - 2650.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Lehtolainen, A. Taskinen, J. Laukkanen, K. J. Airenne, S. Heino, M. Lappalainen, K. Ojala, V. Marjomaki, J. F. Martin, M. S. Kulomaa, et al.
Cloning and Characterization of Scavidin, a Fusion Protein for the Targeted Delivery of Biotinylated Molecules
J. Biol. Chem., March 1, 2002; 277(10): 8545 - 8550.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Reali, J. W. Greiner, A. Corti, H. J. Gould, F. Bottazzoli, G. Paganelli, J. Schlom, and A. G. Siccardi
IgEs Targeted on Tumor Cells: Therapeutic Activity and Potential in the Design of Tumor Vaccines
Cancer Res., July 1, 2001; 61(14): 5517 - 5522.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guttinger, M.
Right arrow Articles by Siccardi, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guttinger, M.
Right arrow Articles by Siccardi, A. G.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online